Compare Dyne Therapeutics Inc. Common Stock (DYN) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs KKR & Co Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while KKR & Co Inc trades at $86.07 (market cap $76.84B). The key difference: KKR & Co Inc is far larger — about 27.3× Dyne Therapeutics Inc. Common Stock's market cap, and KKR & Co Inc pays a 0.91% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and KKR & Co Inc for 67 Days on average.
| DYN | KKR | |
|---|---|---|
Market Cap | $2.81B | $76.84B |
Volume | 2,195,902 | 12,064,615 |
Sector | Health | Financials |
52-Week High | $26.78 | $142.75 |
52-Week Low | $14.60 | $83.88 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $2.13B | -$604.63M |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
KKR trades at $87.16, down 4.75% today, amid bearish technical signals despite strong analyst support. The stock shows mixed fundamentals with a P/E of 27.85 and recent earnings beats, though Q4 2025 missed expectations. Recent corporate activity includes strategic investments in global ventures and a $0.20 dividend declaration. Cash flow trends indicate volatile operational performance, with 2025 net cash flow at $1.78 billion.
Outlook remains cautiously optimistic given 88.9% analyst buy ratings and a $123.20 price target, representing 41% upside. Key risks include execution of recent acquisitions and market sensitivity to private equity cycles. The current dip may present a buying opportunity for long-term investors seeking exposure to alternative asset management growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
